NCT00423514View on ClinicalTrials.gov

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 20, 2006

Primary Completion Date

June 18, 2021

Study Completion Date

June 18, 2021

Conditions

Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes

Interventions

BIOLOGICAL

filgrastim

DRUG

clofarabine

DRUG

melphalan

DRUG

mycophenolate mofetil

DRUG

tacrolimus

DRUG

thiotepa

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00423514 - Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease | Biotech Hunter | Biotech Hunter